Category: Campaigns
A PRIME example of how EMA is pushing for accelerated market approvals, but at what cost for patients?
Joint response of Health Action International (HAI), International Society of Drug Bulletins (ISDB), Mario Negri Institute for Pharmacological Research, Medicines in Europe Forum (MiEF), Nordic Cochrane Centre and Wemos to the European Medicines Agency (EMA) public consultation on the Draft Reflection paper on a proposal to enhance early dialogue to facilitate accelerated assessment of priority medicines (PRIME). Read more…
“Adaptive licensing” or “adaptive pathways”: Deregulation under the guise of earlier access
Joint briefing paper from Health Action International (HAI), The International Society of Drug Bulletins (ISDB), The Medicines in Europe Forum (MiEF), The Mario Negri Institute for Pharmacological Research, The Nordic Cochrane Centre and WEMOS.
ISDB General Assembly Meeting – 2015
The 2015 ISDB General Assembly, Pamplona, Spain, from June 27th to 30th, 2015.
On July 1st there will be a workshop on GRADE method to grading quality of evidence and strength of recommendations. You are also kindly invited to participate in it.
Read more…
European Directive on trade secrets: the JURI Committee must profoundly improve this text
Joint open Letter to the members of the JURI Committee from the Corporate Europe Observatory (CEO), The Medicines in Europe Forum (MiEF) and The International Society of Drug Bulletins (ISDB) calling on the members of the JURI Committee to ensure, through additional and more ambitious amendments, that both freedom of speech for journalists and their sources, including whistle-blowers, and access to regulatory and scientific data of public interest, are preserved.